GLP1 agonist drugs, commonly known by brand names such as Ozempic and Mounjaro, reduce asthma symptoms in obese people ...

While you may start with a certain regimen, you may not sick to it. Here are 7 signs that your asthma medication isn't ...

Swiss drugmaker Roche reported better than expected first-half operating profit on Thursday, driven by strong sales of breast ...

Weight-loss jabs could help minimise asthma symptoms in obese people, according to a study. The drugs should be explored as a ...

WEIGHT loss jabs could help control asthma symptoms in obese people, a study suggests – and it’s not just about losing weight ...

Popular asthma drug Singulair could be linked to mental health side effects, suicides: FDA The medication is "definitely doing something that's concerning," said Julia Marschallinger, a scientist ...

The drug blocks two proteins, interleukin-4 and interleukin-13, that prior research suggested could play critical roles in triggering asthma and other allergy-related diseases.

Early intervention with two asthma drugs may offer protection from pneumonia in patients infected with influenza, according to a new study published in PLOS Pathogens.

Among patients with mild to moderate COVID-19, the asthma drug montelukast (Singulair) did not reduce duration of symptoms, results of the randomized controlled ACTIV-6 trial showed.

Singulair, a popular asthma medication, could be linked to severe side effects, including suicide, a study from the FDA found.